Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study.

Asplund R, Sundberg B, Bengtsson P

BJU international1 Apr 1999Cited by 73 (Europe PMC)

PMID10233563DOI10.1046/j.1464-410x.1999.00012.xPepBankPUB-10233563

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In elderly subjects with nocturia, desmopressin reduced nocturnal diuresis by 0.59 mL/min versus placebo (95% CI 0.33-0.85).
In plain wordsIn elderly subjects with nocturia, desmopressin reduced nocturnal diuresis by 0.59 mL/min compared with placebo.
Peptide
Desmopressin
Outcome
DecreaseNocturnal diuresis
Study
n = 17
Comparator
Placebo
Outcome group
Urine Output · Kidney and urinary
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Measurements
Reduction in nocturnal diuresis
0.59 mL/min
desmopressin versus placebo
95% CI of reduction
0.33 to 0.85 mL/min
desmopressin versus placebo
Source sentences
Summary
Subjects treated with desmopressin had a significantly reduced nocturnal diuresis of 0.59 mL/min compared with those on placebo (95% confidence interval, CI, 0.33-0.85).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356301
02HumanRandomized controlled trialEfficacy outcome
In elderly subjects with nocturia, nighttime micturitions were 1.1 with desmopressin versus 1.7 with placebo (P<0.001; difference 0.59, 95% CI 0.32-0.85).
In plain wordsIn elderly subjects with nocturia, nighttime urination was less frequent with desmopressin than with placebo.
Peptide
Desmopressin
Outcome
DecreaseNocturnal micturitions
Study
n = 17
Comparator
Placebo
Outcome group
Urinary Frequency · Kidney and urinary
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Measurements
Nocturnal micturitions with desmopressin
1.1 micturitions at night
desmopressin
Nocturnal micturitions with placebo
1.7 micturitions at night
placebo
Mean difference
0.59 micturitions at night
desmopressin versus placebo
95% CI of mean difference
0.32 to 0.85 micturitions at night
desmopressin versus placebo
P value
< 0.001 none
nocturnal micturitions, desmopressin versus placebo
Source sentences
Summary
Patients treated with desmopressin had fewer micturitions at night than had those on placebo (1.1 and 1.7, respectively; P<0.001; mean difference=0.59; 95% CI, 0.32-0.85).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356303
03HumanNon-randomized trialEfficacy outcome
In elderly subjects with nocturia, desmopressin did not affect 24-h diuresis.
In plain wordsIn elderly subjects with nocturia, desmopressin did not affect total daily urine output.
Peptide
Desmopressin
Outcome
No significant change24-hour diuresis
Study
n = 17
Outcome group
Urine Output · Kidney and urinary
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Source sentences
Summary
The 24-h diuresis was unaffected by desmopressin treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356302
04HumanNon-randomized trialEfficacy outcome
In elderly subjects with nocturia, diuresis returned to pretreatment levels after desmopressin withdrawal.
In plain wordsIn elderly subjects with nocturia, urine output returned to pretreatment levels after desmopressin stopped.
Peptide
Desmopressin
Outcome
Not applicableDiuresis after withdrawal
Study
n = 17
Comparator
Before treatment
Outcome group
Urine Output · Kidney and urinary
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Source sentences
Summary
After desmopressin treatment was withdrawn, diuresis returned to the levels before treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356306
05HumanNon-randomized trialEfficacy outcome
In elderly subjects with nocturia, desmopressin improved time from sleep onset to first awakening by 1.4 h.
In plain wordsIn elderly subjects with nocturia, the time from falling asleep to first awakening improved by 1.4 hours with desmopressin.
Peptide
Desmopressin
Outcome
Direction not reportedTime to first awakening
Study
n = 17
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Measurements
Improvement in time from falling asleep to first awakening
1.4 h
patients treated with desmopressin
Source sentences
Summary
The time from falling asleep to first awakening was improved by 1.4 h in patients treated with desmopressin.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356307
06HumanNon-randomized trialEfficacy outcome
In elderly subjects with nocturia, body weight did not change during desmopressin treatment.
In plain wordsIn elderly subjects with nocturia, body weight did not change during desmopressin treatment.
Peptide
Desmopressin
Outcome
No significant changeBody weight
Study
n = 17
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Source sentences
Summary
There was no change in body weight or ankle circumference during desmopressin treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356308
07HumanNon-randomized trialEfficacy outcome
In elderly subjects with nocturia, ankle circumference did not change during desmopressin treatment.
In plain wordsIn elderly subjects with nocturia, ankle circumference did not change during desmopressin treatment.
Peptide
Desmopressin
Outcome
No significant changeAnkle circumference
Study
n = 17
Outcome group
Vascular function · Kidney and urinary
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Source sentences
Summary
There was no change in body weight or ankle circumference during desmopressin treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356309
08HumanNon-randomized trialSafety outcome
In elderly subjects with nocturia, desmopressin was well tolerated and no serious adverse events occurred.
In plain wordsIn elderly subjects with nocturia, desmopressin was well tolerated and no serious adverse events occurred.
Peptide
Desmopressin
Outcome
Not applicableSerious adverse events
Study
n = 17
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Source sentences
Summary
Overall, the treatment was well tolerated and no serious adverse events were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356310
09HumanObservational studyOther
In elderly subjects, desmopressin's nocturnal diuresis reduction depended on baseline nighttime diuresis (r=0.886; r2=0.785; P<0.0001).
In plain wordsIn elderly subjects, the reduction in nighttime urine with desmopressin was linked to baseline nighttime urine output.
Peptide
Desmopressin
Outcome
Not applicableResponse correlation with baseline nighttime diuresis
Study
n = 17
Outcome group
Urine Output · Kidney and urinary
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Measurements
Correlation r
0.886 none
reduction in nocturnal diuresis versus baseline night-time diuresis
r2
0.785 none
reduction in nocturnal diuresis versus baseline night-time diuresis
P value
< 0.0001 none
correlation with baseline night-time diuresis
Source sentences
Summary
The reduction in nocturnal diuresis was dependent on the baseline level of night-time diuresis (r=0.886; r2=0.785; P<0.0001) and the nocturnal part of the baseline 24 h-diuresis (r=0.708; r2=0.502; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356304
10HumanObservational studyOther
In elderly subjects, desmopressin's nocturnal diuresis reduction depended on the baseline nocturnal share of daily diuresis (r=0.708; r2=0.502; P<0.001).
In plain wordsIn elderly subjects, desmopressin response was linked to the baseline nighttime share of daily urine output.
Peptide
Desmopressin
Outcome
Not applicableResponse correlation with nocturnal share of daily diuresis
Study
n = 17
Outcome group
Urine Output · Kidney and urinary
Studied dose
Dose not stated · oral · 2 weeksAs given in this study (human).
Measurements
Correlation r
0.708 none
reduction in nocturnal diuresis versus nocturnal part of baseline 24-h diuresis
r2
0.502 none
reduction in nocturnal diuresis versus nocturnal part of baseline 24-h diuresis
P value
< 0.001 none
correlation with nocturnal part of baseline 24-h diuresis
Source sentences
Summary
The reduction in nocturnal diuresis was dependent on the baseline level of night-time diuresis (r=0.886; r2=0.785; P<0.0001) and the nocturnal part of the baseline 24 h-diuresis (r=0.708; r2=0.502; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve men and five women (mean age 67.7 years, sd 4.6 years) met these criteria and were treated with oral desmopressin or placebo at bedtime for 2 weeks on each medication in a randomized, double-blind, crossover design.
Report a problemFND-1023356305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.